IgA nephropathy is the most common primary glomerulonephritis, yet it had no disease-specific therapy until 2021, and 30-40% of patients still progress to kidney failure.

IgA nephropathy is a primary glomerular disease driven by circulating galactose-deficient IgA1: autoantibodies form immune complexes that deposit in the glomerular mesangium, activate complement and drive progressive kidney injury. It is the most common biopsy-proven primary glomerulonephritis. In a large, racially and ethnically diverse US population, adult incidence ran roughly 1.29 to 2.2 new cases per 100,000 per year, highest among patients of Asian ancestry and lowest among Black patients. Because a confirmed diagnosis requires a kidney biopsy, milder disease managed simply as chronic kidney disease without biopsy goes uncounted, so the diagnosed pool understates true prevalence.

The disease is slow but rarely benign. Between 30% and 40% of patients progress to end-stage kidney disease over 20 to 30 years, and registry data put median kidney survival at roughly 11 years from diagnosis for patients under nephrology follow-up. Proteinuria and eGFR trajectory are the validated markers of long-term outcome, and that evidence base underwrote a fast-moving therapeutic shift: from renin-angiotensin-system blockade plus an SGLT2 inhibitor as the supportive-care backbone to five FDA-approved disease-modifying agents spanning four mechanisms, approved between 2021 and 2026.

The therapeutic shift outpaced the diagnostic pathway that still gates it.

Five questions this report answers:

Q1 - How large is the US IgAN population, and how much disease does the biopsy requirement miss?

Q2 - How do kidney biopsy and the Oxford MEST-C classification define IgAN risk?

Q3 - How does the 2021-2026 approval wave change management alongside KDIGO 2025 guidance?

Q4 - How does IgAN incidence vary by race and ethnicity in the US?

Q5 - What share of IgAN patients progress to kidney failure over time?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #IgAN #KidneyDisease #Nephrology #RareDisease #USHealthcare

Live report page:  https://axlrx.ai/iga-nephropathy/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

IgA nephropathy drives 10-12% of incident UK end-stage renal disease, a burden NICE built into its budesonide and sparsentan case.

IgA nephropathy is an immune-mediated glomerulonephritis caused by mesangial deposition of galactose-deficient IgA1, driving progressive proteinuria and declining eGFR. The UK Renal Registry identifies IgAN as the UK's second most common primary glomerulonephritis after membranous nephropathy, with an estimated 10,000-15,000 UK patients and approximately 500 new diagnoses a year confirmed via kidney biopsy. IgAN accounts for 10-12% of incident UK end-stage renal disease, roughly 1,000-1,200 UK ESRD cases annually. A network of approximately 80 NHS specialist nephrology centres performs the confirmatory biopsies, giving the UK a comparatively high diagnosis rate.

The Renal Association's IgAN guideline, aligned with KDIGO 2021, directs optimal ACEi/ARB therapy for three to six months before considering novel agents, targeting blood pressure below 130/80mmHg and a UPCR below 0.5g/g. Corticosteroid immunosuppression remains controversial following the STOP-IgAN trial's null result in high-risk patients, with SGLT2 inhibition now being explored. Both novel agents have since cleared NICE technology appraisal: targeted-release budesonide under TA937, updated by TA1128 in 2026, and sparsentan under TA1074 in June 2025, following MHRA approval of sparsentan in April 2025, moving IgAN novel-agent access from a Named Patient Programme into mainstream NHS commissioning.

Two novel agents cleared NICE; the eligible population sits behind ACEi/ARB failure first.

Five questions this report answers:

Q1 - What is the size of the UK IgAN population eligible for novel agents after ACEi/ARB fails?

Q2 - What is the NHS economic case for novel IgAN agents built on ESRD cost offset?

Q3 - How do the budesonide (TA937/TA1128) and sparsentan (TA1074) NICE recommendations compare on funding?

Q4 - How many NHS nephrology centres perform the biopsies that confirm an IgAN diagnosis?

Q5 - Why did the STOP-IgAN trial leave corticosteroid use controversial in high-risk patients?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #UKRenal #NICE #NHS #NephrologyMarket #DiseaseLandscape

Live report page:  https://axlrx.ai/iga-nephropathy/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

GCC nephrologists biopsy fewer than 30% of eligible proteinuric patients, versus roughly 70% in Japan and Germany, masking IgAN.

IgA nephropathy is estimated to affect 8,000 to 12,000 patients across the GCC, but the true IgAN fraction of incident CKD is difficult to establish. Most proteinuric patients in the region are attributed to diabetic nephropathy, reflecting the GCC's 35% to 40% adult diabetes prevalence, without a confirmatory kidney biopsy. KDIGO guidance calls for biopsy in non-diabetic proteinuria, yet a GCC nephrology network capacity survey finds biopsy performed in fewer than 30% of eligible proteinuric patients, versus roughly 70% in Japan and Germany. Under-biopsy is functionally equivalent to under-diagnosis: a patient never biopsied cannot be coded as IgAN.

Once diagnosed, GCC IgAN patients progress to end-stage renal disease 15% to 20% faster than European observational cohorts, consistent with later diagnosis, poorly controlled hypertension (mean systolic blood pressure at diagnosis of 148mmHg versus a sub-130mmHg target), and late initiation of ACE inhibitor or ARB therapy. Kidney biopsy capability is concentrated at fewer than 20 GCC centres with dedicated nephrology and interventional radiology teams; the patient journey from proteinuria detection to diagnosis typically takes 12 to 24 months, roughly double the 6 to 12 month European benchmark. GCC patients reaching ESRD represent a meaningful share of the region's dialysis population, with IgAN contributing an estimated 12% to 15%.

Diabetes is absorbing a kidney disease population that biopsy would reveal.

Five questions this report answers:

Q1 - How large is the true GCC IgAN population once corrected for diabetes misattribution?

Q2 - Which GCC nephrology centres have kidney biopsy capacity, and how does that gate access to novel therapy?

Q3 - What does ACEi/ARB-first standard of care mean for budesonide and sparsentan entry?

Q4 - What diagnostic and access barriers define the addressable GCC IgA nephropathy market?

Q5 - Why do GCC IgAN patients reach ESRD 15-20% faster than European cohorts?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #Nephrology #RareDisease #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/iga-nephropathy/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

One in 50,000 Americans has HAE, yet laryngeal attacks are just 0.9% of episodes and still drive nearly all its mortality.

Hereditary angioedema is an autosomal-dominant disorder of the SERPING1 gene that leaves C1-esterase inhibitor either too scarce (Type I, roughly 85% of patients) or too dysfunctional (Type II, roughly 15%). The result is unchecked plasma-kallikrein activity and bradykinin overproduction, the mediator behind recurrent, non-itchy swelling that has nothing to do with a typical allergic reaction. US prevalence sits near 1 in 50,000, based on patient-advocacy estimates rather than a peer-reviewed count, and because inheritance is autosomal dominant, every child of an affected parent carries a 50% risk of inheriting the condition.

Symptoms typically begin around age 11 and recur for life. A natural-history cohort of 221 patients tracked 131,110 attack episodes and found cutaneous and abdominal swellings made up 97.4% of them, while laryngeal episodes were only 0.9%, yet they carry essentially all of the disease's mortality risk. Abdominal attacks bring crampy pain, vomiting in 73% of episodes and diarrhoea in 41%, closely mimicking an acute abdomen and often leading to unnecessary surgery before HAE is even considered. Laryngeal attacks kill disproportionately in patients whose disease was never diagnosed, which is why diagnosis, confirmed by a low C4 alongside reduced C1-inhibitor level or function, matters more than any new therapy.

Earlier recognition, not new therapy, is the pivotal commercial and clinical lever.

Five questions this report answers:

Q1 - How large is the US HAE population, and how does the Type I/II split shape the prophylaxis pool?

Q2 - What does the HAE attack burden look like across cutaneous, abdominal and laryngeal attacks?

Q3 - Where is the diagnostic delay in US HAE, and what is the undiagnosed pool worth commercially?

Q4 - How do Type I and Type II HAE differ in C1-inhibitor levels and function?

Q5 - Which HAE attacks are most dangerous, and why do they carry the highest mortality risk?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#HereditaryAngioedema #HAE #RareDisease #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/hereditary-angioedema/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

NICE TA606 lanadelumab cut UK HAE attack frequency from 12 a year to 1.5, an 87% reduction.

Hereditary angioedema is a genetic disorder of the complement and kinin cascade causing recurrent, unpredictable subcutaneous and submucosal swelling episodes, with laryngeal attacks carrying fatal risk if untreated. The UK HAE Alliance estimates 1,500 to 2,000 UK patients, approximately 1 in 32,000 of the population. HAE with C1-inhibitor deficiency, Type 1 or 2, accounts for roughly 85% of cases, with HAE with normal C1-INH, either oestrogen-related or FXII mutation-driven, making up the remaining 15%.

NHS Genomic Medicine Service offers free SERPING1 gene testing as part of the immunodeficiency and angioedema gene panel, driving one of the highest diagnosis rates globally. UK HAE Alliance survey data show mean attack frequency falling from 12 attacks a year before lanadelumab to 1.5 attacks a year after NICE TA606 commissioning, an 87% reduction consistent with the HELP trial, with annual emergency room attendance for laryngeal HAE falling from 45% to under 5%.

One NICE decision cut UK HAE attacks by 87%.

Five questions this report answers:

Q1 - What is the size of the NHS-commissioned HAE prophylaxis population pending berotralstat review?

Q2 - How does NHS GMS SERPING1 cascade testing drive UK HAE diagnosis rates?

Q3 - What has NICE TA606 lanadelumab commissioning changed about UK HAE disease burden?

Q4 - How has NICE TA606 lanadelumab changed UK HAE disease burden under NHS care?

Q5 - How far has laryngeal HAE ER attendance fallen since NICE TA606 commissioning?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#HAE #HereditaryAngioedema #NICE #NHS #UKHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/hereditary-angioedema/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

KFSH&RC's HAE registry finds 3.8 relatives per index case, double Europe's rate, yet fewer than 200 GCC patients are confirmed.

Hereditary angioedema is an autosomal dominant disorder of C1 esterase inhibitor deficiency or dysfunction, producing recurrent, unpredictable attacks of subcutaneous and submucosal swelling. Background prevalence is roughly 1 in 50,000, but GCC family structures, an average of three to four children per family plus extended-family clustering, mean a single index diagnosis carries direct implications for six to twelve relatives. The KFSH&RC HAE registry documents an average of 3.8 affected family members identified per index case, more than double the 1.8 average reported in Europe, making family cascade screening the highest-yield diagnostic strategy available in the region.

Untreated or under-treated GCC HAE patients experience six to twelve attacks per year, with laryngeal attacks, the life-threatening presentation carrying roughly 50% mortality if untreated, accounting for approximately 30% of episodes, a higher share than most global series. GCC emergency physicians rarely include HAE in the differential for laryngeal oedema, and general practitioners typically do not order the C4, C1-INH level, and C1-INH functional assay panel required for diagnosis unless a patient is referred to specialist allergy or immunology services. The result is an estimated 1,200 to 1,500 true GCC HAE patients, of whom fewer than 200 are confirmed.

Family screening, not new diagnostics, is the fastest way to find these patients.

Five questions this report answers:

Q1 - How many undiagnosed GCC HAE patients could family cascade screening identify after an index diagnosis?

Q2 - Why do GCC emergency and primary care physicians miss HAE in the differential for recurrent angioedema?

Q3 - What is the NPHC/MOH formulary trajectory for prophylactic therapy (lanadelumab) across GCC states?

Q4 - What diagnostic and access barriers define the addressable GCC HAE market?

Q5 - Why do laryngeal attacks account for roughly 30% of GCC HAE episodes, higher than global series?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#HAE #HereditaryAngioedema #RareDisease #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/hereditary-angioedema/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

Gaucher type 1 concentrates in the Ashkenazi Jewish founder population at 1 in 500-1,000, and the same genotype carries a near 20-fold Parkinson's risk.

Gaucher disease is an autosomal-recessive lysosomal storage disorder caused by biallelic mutations in GBA1, producing deficient acid beta-glucosidase and a buildup of glucosylceramide in macrophages that infiltrate spleen, liver and bone marrow. Disease divides into three types by neurological involvement: type 1, non-neuronopathic, accounts for more than 90% of patients, while types 2 and 3, far rarer, involve progressive central nervous system degeneration. Type 1 presents with splenomegaly, an enlarged liver, anaemia, low platelets and skeletal disease, not the CNS decline that defines the other two types.

Genotype predicts phenotype. The N370S variant, present on at least one allele, protects against neuronopathic disease and defines type 1; the L444P variant in the homozygous state is linked to the neuronopathic forms. Type 1 is markedly enriched in the Ashkenazi Jewish population, where carrier frequency runs about 1 in 12 to 15 and disease frequency roughly 1 in 500 to 1,000, versus 0.70 to 1.75 per 100,000 in the general population. Many 'asymptomatic' N370S homozygotes in fact have measurable anaemia or an enlarged spleen on evaluation. GBA1 is also the single most common genetic risk factor for Parkinson's disease, and diagnosed type 1 patients carry a lifetime risk ratio of 21.4.

The genotype that protects against neuronopathic Gaucher also predicts Parkinson's risk.

Five questions this report answers:

Q1 - How does the Ashkenazi Jewish founder effect concentrate US Gaucher prevalence?

Q2 - How does GBA1 genotype predict the type 1, 2 and 3 split?

Q3 - Where does the GBA1-Parkinson's link create screening opportunity?

Q4 - How common is Gaucher disease type 1 in the US?

Q5 - How do N370S and L444P variants differ in disease outcome?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#GaucherDisease #GBA1 #RareDisease #LysosomalStorageDisorder #AshkenaziJewish #USHealthcare

Live report page:  https://axlrx.ai/gaucher-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

Fabry disease has two faces: a classic childhood form, and a later-onset cardiac form that is far more common, yet mostly undiagnosed.

Fabry disease is an X-linked lysosomal storage disorder caused by GLA mutations that reduce or abolish alpha-galactosidase A activity, letting globotriaosylceramide build up in the vascular endothelium, kidney, heart and nervous system. Classic Fabry, with near-absent enzyme activity, presents in childhood with neuropathic pain, angiokeratoma and reduced sweating, progressing over decades to renal failure, hypertrophic cardiomyopathy and stroke. US prevalence of diagnosed classic Fabry is estimated at 5,000 to 10,000 patients, about 1 in 40,000 males, but that figure counts only the recognised population.

The larger, quieter story is the later-onset phenotype. Patients with residual enzyme activity often present in their fifties or sixties with isolated cardiac or kidney disease and are frequently missed. Long-term registry data show the leading cause of death shifting from renal failure toward cardiac disease as kidney management has improved. Because Fabry is X-linked, female heterozygotes are not merely carriers; many develop significant multi-organ disease, typically about a decade later than males. Layered on top is the treatment split: roughly 35% to 50% of patients carry a GLA mutation amenable to the oral chaperone migalastat, and the rest depend on intravenous enzyme replacement.

The undiagnosed later-onset cardiac pool may outsize the classic Fabry population.

Five questions this report answers:

Q1 - How large is the undiagnosed later-onset Fabry pool in the US?

Q2 - How does the Fabry organ timeline unfold from childhood pain to organ failure?

Q3 - How does GLA-mutation amenability split patients into oral-chaperone versus ERT-only groups?

Q4 - How common is diagnosed classic Fabry disease among US males?

Q5 - Why has cardiac disease overtaken renal failure as Fabry's leading cause of death?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#FabryDisease #LysosomalStorageDisorder #RareDisease #Nephrology #Cardiology #USHealthcare

Live report page:  https://axlrx.ai/fabry-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

The UK Fabry Outcome Survey tracks roughly 600 of the UK's estimated 800 diagnosed Fabry patients longitudinally.

Fabry disease is an X-linked lysosomal storage disorder caused by alpha-galactosidase A deficiency. An estimated 800 patients are diagnosed in the UK, managed through NHS Highly Specialised Services at lysosomal storage disorder centres in London, Manchester, Cambridge, Birmingham, Edinburgh, and Belfast. The UK Fabry Outcome Survey, a Sanofi-sponsored longitudinal registry, tracks roughly 600 UK patients, giving the UK one of the best-characterised Fabry populations globally, with data showing proteinuria in 55% of males and 35% of females at diagnosis, left ventricular hypertrophy in 60% of males, and neuropathic pain reported by 85% of patients at some point in their disease course.

The NHS Genomic Medicine Service offers free GLA gene testing for probands and first-degree relatives, with genetic counselling before and after testing. This drives a family-cascade yield the UK FOS estimates at 3-4 additional diagnosed relatives per index case, giving the UK the highest per-capita Fabry diagnosis rate in Europe. Both treatment pathways are NHS-commissioned: enzyme replacement therapy for all patients, which has never been formally appraised by NICE and is commissioned via clinical policy, and oral migalastat, NICE HST4 with a patient access scheme, for the roughly 35-50% of patients whose GLA mutation is amenable, confirmed via an assay available at three NHS genetics labs. On treatment, UK FOS data shows renal function stabilisation in around 70% of patients.

Diagnosis is well-characterised; the amenable-mutation split still decides which therapy a patient gets.

Five questions this report answers:

Q1 - How does the NHS specialist-centre network shape diagnosis and outcomes tracking for UK Fabry disease?

Q2 - What share of the UK Fabry population is amenable-mutation eligible for oral migalastat?

Q3 - How does free NHS cascade testing drive Fabry diagnosis rates in the UK?

Q4 - What proportion of UK Fabry patients show neuropathic pain at some point in their disease?

Q5 - How many NHS centres manage lysosomal storage disorder patients across the UK?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#FabryDisease #NICE #NHS #RareDisease #LysosomalStorageDisorder #UK

Live report page:  https://axlrx.ai/fabry-disease/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

GCC Fabry disease access is infrastructure-gated, not formulary-gated: both ERT and oral therapy are covered, yet diagnosis in women lags.

Fabry disease prevalence in GCC males is estimated at 1 in 20,000 to 30,000 versus roughly 1 in 40,000 globally, with specific Arabian Peninsula founder mutations documented at KFSH&RC that create family clusters of 4 to 8 affected males across 2 to 3 GCC generations. Total diagnosed Fabry patients across the GCC number approximately 200 to 300, but true prevalence is likely 3 to 5 times higher given the diagnostic gap, especially in heterozygous females. GCC male patients present with more advanced renal involvement at diagnosis than European cohorts, a median GFR of 45 to 55 mL/min versus 65 to 75 mL/min in Europe.

Heterozygous female Fabry disease, which causes significant morbidity including GFR decline, white matter lesions, and cardiomyopathy despite X-linked inheritance, is systematically under-identified across the GCC: women rarely undergo cascade screening after a male family member's diagnosis. Estimated female Fabry patients run 2 to 3 times the male burden, yet diagnosed female cases represent fewer than half the male diagnosis rate. Both enzyme replacement therapy (agalsidase beta) and oral chaperone therapy (migalastat, for amenable mutations) are NPHC-covered, but migalastat uptake is constrained by HEK cell assay availability limited to KFSH&RC alone.

Women carry most of the undiagnosed Fabry disease burden in the GCC.

Five questions this report answers:

Q1 - How many GCC Fabry patients remain undiagnosed once corrected for the female screening gap?

Q2 - Why do GCC male Fabry patients present with more advanced renal disease than European cohorts?

Q3 - What does the single HEK assay bottleneck mean for migalastat uptake against ERT?

Q4 - What diagnostic and access barriers define the addressable GCC Fabry disease market?

Q5 - Why does GCC Fabry disease access depend on infrastructure rather than formulary coverage?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#FabryDisease #RareDisease #LysosomalStorageDisorder #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/fabry-disease/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/